The correlation between serum apolipoprotein B/apolipoprotein A1 ratio and brain necrosis in patients underwent radiotherapy for nasopharyngeal carcinoma

Abstract

Introduction The apolipoprotein B/apolipoprotein A1 (ApoB/ApoA1) ratio is recognized as a clinical indicator of cardiovascular disease and ischemic cerebral disease. Cerebrovascular dysfunction is also involved in head and neck radiotherapy. The aim of this study was to investigate the correlation between ApoB/ApoA1 ratio and the severity of radiation‐induced brain necrosis (RN) in patients who underwent radiotherapy after nasopharyngeal carcinoma (NPC). Methods In this retrospective study, 191 NPC patients diagnosed with RN were evaluated. Clinical characteristics, serum lipid, apolipoproteins, and brain magnetic resonance imaging findings were collected. Serum lipid and apolipoproteins were quantified using standard diagnostic assays, and the quality of life (QOL) was assessed by the World Health Organization quality of life abbreviated instrument (WHOQOL‐BREF). Results ApoB/ApoA1 ratio was positively correlated with lesion volume (r = .18, p = .03) and negatively correlated with WHOQOL‐BREF scores (r = −.28, p < .01). The ApoB/ApoA1 ratio and intensity‐modulated radiation therapy (IMRT) were independent risk factor of RN volume. Moreover, ApoB/ApoA1 ratio was significantly negatively correlated with physical health (r = −.29, p < .01), psychological (r = −.27, p < .01), social relationships (r = −.17, p = .02), and environment (r = −.27, p < .01) domains of WHOQOL‐BREF. Conclusions Serum ApoB/ApoA1 ratio is positively correlated with RN volume, which indicated serum ApoB/ApoA1 ratio as an independent risk factor for lesion volume in patients with RN after radiotherapy for NPC, suggesting a bright intervention target in RN treatment.

Enhancing prognostic accuracy in head and neck squamous cell carcinoma chemotherapy via a lipid metabolism-related clustered polygenic model

“…Remarkably, the subsequent analysis found that the established LMRS model performed well in evaluating the survival outcome and drug response of HNSCCs and performed with similar efficacy to that of the 751 lipid metabolism gene model. Although not every gene was differentially expressed in the TCGA-HNSCC database, the LMRS model highlighted frequently altered genes in HNSCCs, such as IKBKB [ 32 ], MAPK9 [ 38 ], and APOB [ 34 ]. Moreover, when combined with age, gender, tumor stage, pathological classification, and smoking status, the LMRS model effectively predicted short-term and medium-term diagnostic values, surpassing other clinical parameters, such as age and gender.…”